STOCK TITAN

Bicara Therapeutics (BCAX) CMO awarded 85,000 options at $22.58 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reported that Chief Medical Officer William Schelman received a grant of stock options covering 85,000 shares of common stock. The options have an exercise price of $22.58 per share and expire on May 8, 2036.

According to the terms, the shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, contingent on his continued service. After this grant, Schelman holds options for 85,000 shares directly, reflecting a routine compensation-related award rather than an open-market trade.

Positive

  • None.

Negative

  • None.
Insider Schelman William
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 85,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 85,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 85,000 options Stock Option (Right to Buy) granted to CMO
Exercise price $22.58 per share Conversion/exercise price of granted options
Expiration date May 8, 2036 Option expiration for the 85,000-share grant
Underlying shares 85,000 shares Common stock underlying the stock option grant
Vesting schedule 16 equal quarterly installments Vesting begins after May 8, 2026, subject to service
Holdings after grant 85,000 options Total derivative shares following transaction
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 22.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-05-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Chief Medical Officer financial
"officer_title: Chief Medical Officer"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schelman William

(Last)(First)(Middle)
116 HUNTINGTON AVE, SUITE 703

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$22.5805/08/2026A85,000 (1)05/08/2036Common Stock85,000$085,000D
Explanation of Responses:
1. The shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, subject to the Reporting Person's continued service on each such vesting date.
Remarks:
/s/ Lara Meisner, Attorney-in-Fact05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bicara Therapeutics (BCAX) disclose about William Schelman in this Form 4?

Bicara Therapeutics disclosed that Chief Medical Officer William Schelman received a grant of stock options for 85,000 shares. These options are compensation-related, not an open-market purchase or sale, and give him the right to buy common stock at a set exercise price.

How many stock options did the Bicara (BCAX) CMO receive and at what exercise price?

The Chief Medical Officer received options covering 85,000 shares of common stock with an exercise price of $22.58 per share. This award is recorded as a grant under transaction code A, representing a grant, award, or other acquisition of derivative securities.

When do William Schelman’s Bicara (BCAX) stock options vest and expire?

The options vest in sixteen equal quarterly installments following May 8, 2026, subject to his continued service on each vesting date. They have an expiration date of May 8, 2036, providing a long-dated incentive horizon for the Chief Medical Officer.

Is the Bicara (BCAX) Form 4 for William Schelman an open-market trade?

No, the Form 4 reflects a compensation grant, not an open-market trade. The transaction code A indicates a grant, award, or other acquisition of derivative securities, and the exercise price is set at $22.58 per share with vesting conditions tied to continued service.

How many Bicara (BCAX) options does William Schelman hold after this transaction?

After this grant, William Schelman holds options for 85,000 shares of Bicara common stock directly. These options were all acquired in this single grant and represent his derivative position as shown in the filing, with no additional derivative holdings listed.